Letter to the Editor
Light at the end of the tunnel of preserved heart failure, although important improvements are still necessary
Insuficiência cardíaca com fração de ejeção preservada – luz ao fundo túnel, apesar de ainda serem necessárias melhorias importantes
Lido
1403
Vezesque se leu este artigo
622
Total PDF
781
Total HTML
Compartilhar estatísticas
array:23 [ "pii" => "S0870255122003468" "issn" => "08702551" "doi" => "10.1016/j.repc.2022.01.008" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "2012" "copyright" => "Sociedade Portuguesa de Cardiologia" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Rev Port Cardiol. 2022;41:897-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemAnterior" => array:19 [ "pii" => "S0870255122003523" "issn" => "08702551" "doi" => "10.1016/j.repc.2022.08.004" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "2017" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Rev Port Cardiol. 2022;41:895" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Reply to the Letter to the Editor: Takotsubo syndrome in the setting of COVID-19: Pathogenetic and diagnostic implications" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "895" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Resposta à Carta ao Editor: Síndrome de Takotsubo no contexto da COVID-19: ımplicações patogénicas e diagnósticas" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Kristian Rivera, Diego Fernández-Rodríguez, Marta Zielonka, Juan Casanova-Sandoval" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Kristian" "apellidos" => "Rivera" ] 1 => array:2 [ "nombre" => "Diego" "apellidos" => "Fernández-Rodríguez" ] 2 => array:2 [ "nombre" => "Marta" "apellidos" => "Zielonka" ] 3 => array:2 [ "nombre" => "Juan" "apellidos" => "Casanova-Sandoval" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255122003523?idApp=UINPBA00004E" "url" => "/08702551/0000004100000010/v1_202210061538/S0870255122003523/v1_202210061538/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Light at the end of the tunnel of preserved heart failure, although important improvements are still necessary" "tieneTextoCompleto" => true "saludo" => "To the Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "897" "paginaFinal" => "898" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Julio Núñez, Rafael de la Espriella, Francesc Formiga" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Julio" "apellidos" => "Núñez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Rafael" "apellidos" => "de la Espriella" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:4 [ "nombre" => "Francesc" "apellidos" => "Formiga" "email" => array:1 [ 0 => "fformiga@bellvitgehospital.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Geriatric Unit, Internal Medicine Department, Hospital Universitari de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Insuficiência cardíaca com fração de ejeção preservada – luz ao fundo túnel, apesar de ainda serem necessárias melhorias importantes" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We read with great interest the manuscript by J Silva-Cardoso et al. entitled “SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction”.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">1</span></a> In their article, the authors performed a literature review to analyze how SGLT-2 inhibitors have emerged as the fourth pillar of pharmacological disease-modifying therapy in heart failure with reduced ejection fraction (HFrEF) patients, regardless of the presence or absence of diabetes.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">1</span></a> After a close reading of the article, we would like to reflect on the current situation of heart failure with preserved ejection fraction (HFpEF).</p><p id="par0010" class="elsevierStylePara elsevierViewall">The extensive evidence with HFrEF lack in HFpEF up to Emperor trial.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">2</span></a> In patients with stable HF and left ventricle ejection fraction >40%, the Emperor trial showed a 21% reduction in the primary endpoint (composite of cardiovascular death or HF hospitalization) at a median follow-up of 26.2 months.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">2</span></a> This effect was mainly due to a decrease in the risk of hospitalization; indeed, patients on empagliflozin showed a reduction of 27% in the total HF hospitalization that occurred during follow-up.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">2</span></a> However, a neutral effect was found for all cause-mortality (hazard ration (HR): 1.00; 95% confidence interval (CI), 0.87-1.15) and total rehospitalizations (HR: 0.93; 95% CI, 0.85-1.01). Interestingly, non-HF hospitalizations and non-CV-death accounted for 84.2% and 48.1% of the total, respectively.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">2</span></a> Observational studies have also confirmed the large proportion of non-CV events in HFpEF patients.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">3,4</span></a> There is no doubt that current findings represent a significant advance in the management of these patients, however, these results merit some reflections.<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1.</span><p id="par0015" class="elsevierStylePara elsevierViewall">HFpEF patients are generally older patients characterized by chronicity and multimorbidity.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">1–5</span></a> Thus, if we aim to decrease morbidity and mortality rather than change the mode in which patients die or are hospitalized, we should recognize HFpEF as a systemic entity rather than just a cardiac issue. Hence, we should: (a) improve our knowledge of the non-CV risk in these patients; (b) increase awareness about it; and (c) promote the creation of multidisciplinary teams to manage non-CV complications properly. The overall assessment of these patients is basic.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2.</span><p id="par0020" class="elsevierStylePara elsevierViewall">From a cardiac point of view, we should also expand the traditional perspective of the syndrome as predominant left-sided heart disease by considering pulmonary circulation and right-sided function.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">6</span></a> There is a homogenous voice/clamor among the scientific community moving toward precision medicine. It is especially crucial in HFpEF, in which the pathophysiology is widely heterogeneous.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">7</span></a> Along this line of thought, compelling evidence points to the relevant clinical role of pulmonary hypertension and right-sided HF in HFpEF. Indeed, recent authors estimate that 30–50% of patients with HFpEF showed PH/right HF-sided phenotype.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">6</span></a> However, it is noteworthy that neither traditional inclusion criteria nor subgroup analyses in HFpEF consider right-sided HF. Indeed, subgroup and post-hoc analyses of HFpEF trials mainly include the same analysis as HFrEF trials. There is no data on the efficacy or safety of HF treatments according to pulmonary hypertension or right-sided HF. We encourage investigators to collect this information and design further trials, not ignoring the other side of the heart. By looking at the heart from another perspective, we may unravel different realities. In a real world of older HFpEF patients, a global assessment of the heart and even more important of the patient is basic.</p></li></ul></p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Author contributions</span><p id="par0025" class="elsevierStylePara elsevierViewall">All authors of this research paper have directly participated in the planning, execution, drafting the study;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Funding</span><p id="par0030" class="elsevierStylePara elsevierViewall">None.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Conflicts of interest</span><p id="par0035" class="elsevierStylePara elsevierViewall">All authors had no conflicts of interest to disclose.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Author contributions" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Funding" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Conflicts of interest" ] 3 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:7 [ 0 => array:3 [ "identificador" => "bib0040" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Silva-Cardoso" 1 => "A. Andrade" 2 => "D. Brito" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Port Cardiol (Engl Ed)" "fecha" => "2021" "volumen" => "40" "paginaInicial" => "687" "paginaFinal" => "693" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0045" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Empagliflozin in heart failure with a preserved ejection fraction" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "EMPEROR-Preserved Trial Investigators" "etal" => true "autores" => array:3 [ 0 => "S.D. Anker" 1 => "J. Butler" 2 => "G. Filippatos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2107038" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2021" "volumen" => "385" "paginaInicial" => "1451" "paginaFinal" => "1461" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34449189" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0050" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R.J. Mentz" 1 => "J.P. Kelly" 2 => "T.G. von Lueder" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2014.08.036" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2014" "volumen" => "64" "paginaInicial" => "2281" "paginaFinal" => "2293" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25456761" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0055" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Burden of recurrent hospitalizations following an admission for acute heart failure: preserved versus reduced ejection fraction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E. Santas" 1 => "E. Valero" 2 => "A. Mollar" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Esp Cardiol (Engl Ed)" "fecha" => "2017" "volumen" => "70" "paginaInicial" => "239" "paginaFinal" => "246" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0060" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Heart failure with preserved ejection fraction. A dim light at the end of the tunnel" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F. Formiga" 1 => "M.T. Vidán" 2 => "J. Nuñez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.regg.2019.09.003" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Geriatr Gerontol" "fecha" => "2019" "volumen" => "54" "paginaInicial" => "307" "paginaFinal" => "308" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31668483" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0065" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Right heart phenotype in heart failure with preserved ejection fraction" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Guazzi" 1 => "R. Naeije" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCHEARTFAILURE.120.007840" "Revista" => array:5 [ "tituloSerie" => "Circ Heart Fail" "fecha" => "2021" "volumen" => "14" "paginaInicial" => "e007840" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33866826" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0070" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "ESC Scientific Document Group" "etal" => true "autores" => array:3 [ 0 => "T.A. McDonagh" 1 => "M. Metra" 2 => "M. Adamo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehab368" "Revista" => array:7 [ "tituloSerie" => "Eur Heart J" "fecha" => "2021" "volumen" => "42" "paginaInicial" => "3599" "paginaFinal" => "3726" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34447992" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1472648318303262" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/08702551/0000004100000010/v1_202210061538/S0870255122003468/v1_202210061538/en/main.assets" "Apartado" => array:4 [ "identificador" => "94361" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editors" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/08702551/0000004100000010/v1_202210061538/S0870255122003468/v1_202210061538/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255122003468?idApp=UINPBA00004E" ]
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2024 Novembro | 10 | 8 | 18 |
| 2024 Outubro | 39 | 36 | 75 |
| 2024 Setembro | 40 | 24 | 64 |
| 2024 Agosto | 44 | 28 | 72 |
| 2024 Julho | 35 | 32 | 67 |
| 2024 Junho | 22 | 19 | 41 |
| 2024 Maio | 26 | 27 | 53 |
| 2024 Abril | 31 | 21 | 52 |
| 2024 Maro | 26 | 17 | 43 |
| 2024 Fevereiro | 22 | 26 | 48 |
| 2024 Janeiro | 21 | 18 | 39 |
| 2023 Dezembro | 18 | 16 | 34 |
| 2023 Novembro | 26 | 20 | 46 |
| 2023 Outubro | 17 | 21 | 38 |
| 2023 Setembro | 13 | 20 | 33 |
| 2023 Agosto | 19 | 8 | 27 |
| 2023 Julho | 17 | 16 | 33 |
| 2023 Junho | 25 | 11 | 36 |
| 2023 Maio | 34 | 19 | 53 |
| 2023 Abril | 12 | 9 | 21 |
| 2023 Maro | 37 | 19 | 56 |
| 2023 Fevereiro | 22 | 11 | 33 |
| 2023 Janeiro | 28 | 19 | 47 |
| 2022 Dezembro | 28 | 22 | 50 |
| 2022 Novembro | 40 | 30 | 70 |
| 2022 Outubro | 91 | 62 | 153 |
| 2022 Setembro | 36 | 62 | 98 |
| 2022 Agosto | 2 | 1 | 3 |
Mostrar tudo
